|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park W, Chawla A and O'Reilly EM:
Pancreatic Cancer: A Review. JAMA. 326:851–862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waters AM and Der CJ: KRAS: The critical
driver and therapeutic target for pancreatic cancer. Cold Spring
Harb Perspect Med. 8:a0314352018. View Article : Google Scholar :
|
|
4
|
Wittwer NL, Brown MP, Liapis V and
Staudacher AH: Antibody drug conjugates: Hitting the mark in
pancreatic cancer? J Exp Clin Cancer Res. 42:2802023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crescioli S, Kaplon H, Wang L,
Visweswaraiah J, Kapoor V and Reichert JM: Antibodies to watch in
2025. MAbs;17:24435382025.
|
|
6
|
Ungaro A, Tucci M, Audisio A, Di Prima L,
Pisano C, Turco F, Delcuratolo MD, Di Maio M, Scagliotti GV and
Buttigliero C: Antibody-drug conjugates in urothelial carcinoma: A
new therapeutic opportunity moves from bench to bedside. Cells.
11:8032022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khosravanian MJ, Mirzaei Y, Mer AH,
Keyhani-Khankahdani M, Abdinia FS, Misamogooe F, Amirkhani Z,
Bagheri N, Meyfour A, Jahandideh S, et al: Nectin-4-directed
antibody-drug conjugates (ADCs): Spotlight on preclinical and
clinical evidence. Life Sci. 352:1229102024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Challita-Eid PM, Satpayev D, Yang P, An Z,
Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, et
al: Enfortumab vedotin antibody-drug conjugate targeting nectin-4
is a highly potent therapeutic agent in multiple preclinical cancer
models. Cancer Res. 76:3003–3013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishiwada S, Sho M, Yasuda S, Shimada K,
Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N and Nakajima
Y: Nectin-4 expression contributes to tumor proliferation,
angiogenesis and patient prognosis in human pancreatic cancer. J
Exp Clin Cancer Res. 34:302015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kimmelman AC and White E: Autophagy and
tumor metabolism. Cell Metab. 25:1037–1043. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amaravadi R, Kimmelman AC and White E:
Recent insights into the function of autophagy in cancer. Genes
Dev. 30:1913–1930. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van der Vos KE, Eliasson P,
Proikas-Cezanne T, Vervoort SJ, van Boxtel R, Putker M, van Zutphen
IJ, Mauthe M, Zellmer S, Pals C, et al: Modulation of glutamine
metabolism by the PI(3) K-PKB-FOXO network regulates autophagy. Nat
Cell Biol. 14:829–837. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lahiri V, Hawkins WD and Klionsky DJ:
Watch what you (self-) eat: Autophagic mechanisms that modulate
metabolism. Cell Metab. 29:803–826. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ktistakis NT and Tooze SA: Digesting the
expanding mechanisms of autophagy. Trends Cell Biol. 26:624–635.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo JY, Xia B and White E:
Autophagy-mediated tumor promotion. Cell. 155:1216–1219. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Nan Y, Ma C, Lu X, Wang Q, Huang
X, Xue W, Fan J, Ju D, Ye D and Zhang X: A potential strategy for
bladder cancer treatment: Inhibiting autophagy to enhance antitumor
effects of Nectin-4-MMAE. Cell Death Dis. 15:2932024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu Q, Zhao H, Zhou K, Hua X and Zhang X:
Scarless circular mRNA-based CAR-T cell therapy elicits superior
anti-tumor efficacy. bioRxiv 2024.2008.2005.606578. 2024.
|
|
18
|
Fu Z, Li S, Han S, Shi C and Zhang Y:
Antibody drug conjugate: The 'biological missile' for targeted
cancer therapy. Signal Transduct Target Ther. 7:932022. View Article : Google Scholar
|
|
19
|
Adair JR, Howard PW, Hartley JA, Williams
DG and Chester KA: Antibody-drug conjugates-A perfect synergy.
Expert Opin Biol Ther. 12:1191–1206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X: The expanding role of mitochondria
in apoptosis. Genes Dev. 15:2922–2933. 2001.PubMed/NCBI
|
|
21
|
Zang YD, Wu HJ, Chen XY, Ma ZL, Li CJ, Ma
J, Chen XG, Sheng L, Zhang S and Zhang DM: Synthesis and biological
evaluation of novel Psidium meroterpenoid derivatives against
cisplatin-induced acute kidney injury. J Med Chem. 67:14234–14255.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qu L, Liu Y, Deng J, Ma X and Fan D:
Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent
that regulates autophagy and apoptosis in hepatocellular carcinoma.
J Pharm Anal. 13:463–482. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Mao L, Yu B, Liu H, Zhang Q, Bian Z,
Zhang X, Liao W and Sun S: GB7 acetate, a galbulimima alkaloid from
Galbulimima belgraveana, possesses anticancer effects in colorectal
cancer cells. J Pharm Anal. 12:339–349. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao W, Wang X, Zhou Y, Wang X and Yu Y:
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor
immunotherapy. Signal Transduct Target Ther. 7:1962022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang
X, Huang J, Gai J, Li G, Qiao P, et al: TROP2-directed
nanobody-drug conjugate elicited potent antitumor effect in
pancreatic cancer. J Nanobiotechnology. 21:4102023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu C, Huang X, Hu Q, Xue W, Zhou K, Li X,
Nan Y, Ju D, Wang Z and Zhang X: Modulating autophagy to boost the
antitumor efficacy of TROP2-directed antibody-drug conjugate in
pancreatic cancer. Biomed Pharmacother. 180:1175502024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Witkiewicz AK, McMillan EA, Balaji U, Baek
G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et
al: Whole-exome sequencing of pancreatic cancer defines genetic
diversity and therapeutic targets. Nat Commun. 6:67442015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fang P, You M, Cao Y, Feng Q, Shi L, Wang
J, Sun X, Yu D, Zhou W, Yin L, et al: Development and validation of
bioanalytical assays for the quantification of 9MW2821, a
nectin-4-targeting antibody-drug conjugate. J Pharm Biomed Anal.
248:1163182024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xue W, Xu C, Zhang K, Cui L, Huang X, Nan
Y, Ju D, Chang X and Zhang X: Enhancing antitumor efficacy of
CLDN18.2-directed antibody-drug conjugates through autophagy
inhibition in gastric cancer. Cell Death Discov. 10:3932024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Slominski RM, Raman C, Chen JY and
Slominski AT: How cancer hijacks the body's homeostasis through the
neuroendocrine system. Trends Neurosci. 46:263–275. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen X, Zeh HJ, Kang R, Kroemer G and Tang
D: Cell death in pancreatic cancer: From pathogenesis to therapy.
Nat Rev Gastroenterol Hepatol. 18:804–823. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mottini C, Auciello FR, Manni I, Pilarsky
C, Caputo D, Caracciolo G, Rossetta A, Di Gennaro E, Budillon A,
Blandino G, et al: The cross-talk between the macro and
micro-environment in precursor lesions of pancreatic cancer leads
to new and promising circulating biomarkers. J Exp Clin Cancer Res.
43:1982024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dikic I and Elazar Z: Mechanism and
medical implications of mammalian autophagy. Nat Rev Mol Cell Biol.
19:349–364. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
García-Alonso S, Ocaña A and Pandiella A:
Resistance to antibody-drug conjugates. Cancer Res. 78:2159–2165.
2018. View Article : Google Scholar : PubMed/NCBI
|
